4//SEC Filing
Zheng Yongxiang 4
Accession 0001437749-23-014700
CIK 0001389545other
Filed
May 14, 8:00 PM ET
Accepted
May 15, 6:52 PM ET
Size
6.8 KB
Accession
0001437749-23-014700
Insider Transaction Report
Form 4
Zheng Yongxiang
Director
Transactions
- Exercise/Conversion
Common Stock
2023-05-11+858→ 858 total - Exercise/Conversion
Restricted Stock Units
2023-05-11−858→ 0 total→ Common Stock (858 underlying)
Footnotes (2)
- [F1]On November 15, 2022, NovaBay Pharmaceuticals, Inc. effected a 1-for-35 reverse stock split of its common stock, which is reflected in the number of shares.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vested on the one year anniversary of the date of grant.
Documents
Issuer
NovaBay Pharmaceuticals, Inc.
CIK 0001389545
Entity typeother
Related Parties
1- filerCIK 0001910375
Filing Metadata
- Form type
- 4
- Filed
- May 14, 8:00 PM ET
- Accepted
- May 15, 6:52 PM ET
- Size
- 6.8 KB